What's Going On With Mustang Bio Stock Tuesday?
What's Going On With Mustang Bio Stock Tuesday?
Mustang Bio, Inc. (NASDAQ:MBIO) shares appear to be trending upward Tuesday on continued momentum after the company on Monday announced safety and efficacy data from its Phase 1/2 clinical trial of MB-106, a possible treatment for certain types of blood cancer.
納斯達克（NASDAQ）：此前的週一，Mustang Bio公司宣佈了MB-106一期/二期臨床試驗的安全性和療效數據，這家公司的股票似乎在週二繼續上漲，MB-106可能是治療某些類型血癌的一種可能治療方案。
90% of patients treated with MB-106 responded to the treatment with three complete responses. Out of the three complete responses, one of the participants remains in complete remission at 31 months.
90%的接受MB-106治療的患者都對該治療做出了反應，三名患者完全緩解。在這三名完全緩解的患者中，有一名參與者在31個月後仍處於完全緩解狀態。
Mustang Bio is developing the treatment in collaboration with Fred Hutch Cancer Center. The data was presented at the European Hematology Association 2024 Hybrid Congress.
Mustang Bio與Fred Hutch Cancer Center合作開發這種治療方法。這些數據在2024年歐洲血液學會混合大會上公佈。
MBIO Price Action: Mustang Bio stock is trading 35.9% higher at 99 cents at the time of writing, according to data from Benzinga Pro.
MBIO價格走勢：根據Benzinga Pro數據，Mustang Bio股票在寫作時以99美分的價格上漲了35.9%。
Image: Emilian Danaila from Pixabay
圖片：來自Pixabay的Emilian Danaila
譯文內容由第三人軟體翻譯。